Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
——
Natera, Inc. logo
Natera, Inc.NTRA
——
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Bicara Therapeutics (BCAX) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $10.74 in Q1 2026.
How has Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price increased by 48.1% year-over-year, from $7.25 to $10.74.
What is the long-term trend for Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 2 years (2023 to 2025), Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 41.2% compound annual growth rate (CAGR), from $4.53 to $9.03.